

Altered kynurenine pathway in episodic migraine patients: potential peripheral biomarkers during the interictal period

¹Department of Neurology, ²MTA-SZTE Neuroscience Research Group, ³Department of Radiology, ¹Department of Radiology, ¹Department of Radiology, ²MTA-SZTE Neuroscience Research Group, ³Department of Radiology, ¹Department of Radiology, ¹D Univerity of Szeged, Szeged, Hungary

INTRODUCTION

Altered glutamatergic neurotransmission play a central role in migraine patomechanism. The kynurenine pathway (KP) is closely related to the glutamatergic system. Since the inhibition of N-methyl-D-aspartate (NMDA) receptors is believed to protect against glutamate-caused excitotoxicity, and kynurenic acid (KYNA) – which is one of the metabolite in the KP – has a competitive antagonist effect on these receptors, it is possible that the KP has therapeutic potential in headache disorders.

AIMS

- 1. To determine the concentrations of main metabolites of tryptophan (Trp) pathway in the peripheral plasma of episodic migraine patients compared to healthy subjects.
- To distinguish between metabolic alterations in the interictal/ictal periods and in the two subgroups of patients (migraine with and without aura).
- 3. To describe the relationship between altered Trp metabolism and clinical features of the disease/attacks.


METHODS

- Inclusion criteria: Female episodic migraine (EM) patients fulfilling the criteria of the 3rd edition of The International Classification of Headache Disorders were registered, aged between 25-50 years (n=50) and healthy control subjects (n=34) were recruited.
- Exclusion criteria: both the EM and control group included the presence of other type of headache (e.g tension type headache) less than 48 hours before sampling, or serious systemic disorders, or other chronic pain condition and depression. Blood samples were collected from cubital veins of patienst during the inetrictal (attack free) (n=47) and ictal (attack) (n=12) periods and from healthy controls on one occasion. 12 metabolites of TRP pathway were determined by neurochemical measurements (ultra high performance liquid chromatography-tandem mass spectometry (UHPLC-MS/MS.)

REFERENCES

Tuka et al. Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period. J Headache Pain. 2021 Jun 25;22(1):60.

Aliz Nyári¹, Bernadet Tuka^{1,2}, Edina Katalin Cseh¹, Tamás Körtési^{1,2,5}, Dániel Veréb⁶, Ferenc Tömösi³, Gábor Kecskeméti³, Tamás Janáky³, János Tajti¹, László Vécsei^{1,2,4}



Differences in plasma levels of Trp, KYN, KYNA, ANA, PICA, QUINA and 5-HIAA between groups of interictal/ictal phases of migraine without aura patients and healthy subjects. Significance levels: * p < 0.05, ** p < 0.01, *** p < 0.001.

3D-projection plots of migraine and healthy metabolite profiles in the PLS latent variable space. The classification hyperplane was obtained using linear discriminant analysis.

Supposedly, in the CNS of migraineurs the brain is able to take up Trp from the periphery, to protect the brain from damage (counterbalancing excitotoxicity) (Fig. 2).